GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (NAS:ARNA) » Definitions » Gross Property, Plant and Equipment

Arena Pharmaceuticals (Arena Pharmaceuticals) Gross Property, Plant and Equipment : $75.35 Mil (As of Dec. 2021)


View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Gross Property, Plant and Equipment?

Arena Pharmaceuticals's quarterly gross PPE increased from Jun. 2021 ($74.95 Mil) to Sep. 2021 ($75.07 Mil) and increased from Sep. 2021 ($75.07 Mil) to Dec. 2021 ($75.35 Mil).

Arena Pharmaceuticals's annual gross PPE increased from Dec. 2019 ($73.92 Mil) to Dec. 2020 ($74.75 Mil) and increased from Dec. 2020 ($74.75 Mil) to Dec. 2021 ($75.35 Mil).


Arena Pharmaceuticals Gross Property, Plant and Equipment Historical Data

The historical data trend for Arena Pharmaceuticals's Gross Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Gross Property, Plant and Equipment Chart

Arena Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Gross Property, Plant and Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 88.24 69.54 73.92 74.75 75.35

Arena Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Gross Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.75 74.73 74.95 75.07 75.35

Arena Pharmaceuticals Gross Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the company. Fixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Arena Pharmaceuticals  (NAS:ARNA) Gross Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Arena Pharmaceuticals Gross Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Gross Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Arena Pharmaceuticals (Arena Pharmaceuticals) Business Description

Industry
Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
Executives
Amit Munshi director, officer: President and CEO C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Robert Lisicki officer: EVP, Chief Commercial Officer C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Dallas Jayson Donald Alexander director AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Vincent Aurentz officer: Executive VP and CBO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Christopher Cabell officer: EVP, Head of R&D, and CMO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Kieran Gallahue director PO BOX 684369, PARK CITY UT 84068
Katharine Knobil director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Oliver Fetzer director AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Laurie Stelzer officer: EVP & Chief Financial Officer 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Joan Schmidt officer: EVP, General Counsel & Sec C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Kevin Robert Lind officer: Executive VP and CFO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121

Arena Pharmaceuticals (Arena Pharmaceuticals) Headlines

From GuruFocus